None
Quote | Processa Pharmaceuticals Inc. (OTCMKTS:PCSA)
Last: | $9.94 |
---|---|
Change Percent: | -1.58% |
Open: | $9.99 |
Close: | $9.94 |
High: | $9.99 |
Low: | $9.74 |
Volume: | 800 |
Last Trade Date Time: | 09/23/2020 04:54:08 pm |
News | Processa Pharmaceuticals Inc. (OTCMKTS:PCSA)
Processa Pharmaceuticals (NASDAQ: PCSA) , a clinical-stage pharmaceutical company focused on developing the next generation of chemotherapeutic drugs with improved efficacy and safety, will be represented at this month’s EF Hutton Annual Global Conference. According to the announcement, ke...
HANOVER, Md., May 06, 2024 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical-stage pharmaceutical company focused on developing the next generation of chemotherapeutic drugs with improved efficacy and safety, ...
Message Board Posts | Processa Pharmaceuticals Inc. (OTCMKTS:PCSA)
Subject | By | Source | When |
---|---|---|---|
MomentumIts trading last up | Big Brother | investorshub | 04/27/2023 7:43:58 PM |
got some short data | Renee | investorshub | 04/26/2023 11:02:52 PM |
$PCSA Price now last up | parabol128 | investorshub | 04/26/2023 3:36:22 PM |
$PCSA The trading | Big Brother | investorshub | 04/25/2023 12:34:11 AM |
Good read | Big Brother | investorshub | 04/24/2023 11:12:16 PM |
News, Short Squeeze, Breakout and More Instantly...
Processa Pharmaceuticals Inc. Company Name:
PCSA Stock Symbol:
OTCMKTS Market:
Processa Pharmaceuticals (NASDAQ: PCSA) , a clinical-stage pharmaceutical company focused on developing the next generation of chemotherapeutic drugs with improved efficacy and safety, will be represented at this month’s EF Hutton Annual Global Conference. According to the announcement, ke...
HANOVER, Md., May 06, 2024 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical-stage pharmaceutical company focused on developing the next generation of chemotherapeutic drugs with improved efficacy and safety, ...
Processa (NASDAQ: PCSA) is a clinical-stage pharmaceutical company focused on developing the next generation of chemotherapeutic drugs with improved efficacy and safety. The company today announced that it has named Steven Cha, M.D. as senior vice president of clinical research. In the newly cre...